Company intelligence / Profile preview

AdOM Advanced Optical Technologies

Ownership: Private
Development stage: Commercial

Overview

The company has commercialized the Tear Film Imager device for non-invasive measurement of tear film sublayers. The TFI has received FDA Class I exemption and initial commercialization efforts are focused on major academic medical centers in the U.S. Clinical results have been published in peer-reviewed journals; more than twenty patents granted globally.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Medical Imaging

Drug pipeline

1 asset

Tear Film Imager

Commercial

Indications: Dry eye disease, COVID-19

Partnerships

None listed explicitly. Focused on collaborations with academic medical centers.

Beyond the preview

Go deeper on AdOM Advanced Optical Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdOM Advanced Optical Technologies.

Explore the full profile